1. BRD4 expression levels are associated with sensitivity to BET inhibition in NRAS‐mutant melanoma
BRD4 expression levels are associated with sensitivity to BET inhibition in NRAS‐mutant melanoma ACells were treated with increasing doses of JQ‐1 for 3 days, and the number of viable cells was determined by MTT assays. Concentrations inhibiting 50% of cell growth (IC50) were calculated at day 3 using GraphPad Prism V5.0a. Bottom panel: Expression of BRD4 was assessed by immunoblotting; β‐actin was used as loading control. Representative Western blot is shown.BQuantification of BRD4 protein levels from immunoblots is shown. Membranes were scanned and quantified using the LI‐COR Odyssey system; average protein levels from three independent experiments ± SEM are depicted in the bar graphs.CLinear correlation between BRD4 protein levels and JQ‐1 IC50 was assessed using Pearson's correlation coefficient. Data analysis was performed using Stata version 13.DExpression of BRD2 and BRD3 was evaluated by Western blot in a panel of NRAS‐mutant melanoma and non‐transformed cell lines.E, FQuantification of BRD2 (E) and BRD3 (F) protein levels from immunoblots is shown. Membranes were scanned and quantified using the LI‐COR Odyssey system; average protein levels from three independent experiments ± SEM are depicted in the bar graphs.G, HLinear correlation between BRD2 (G) and BRD3 (H) protein levels and JQ‐1 IC50 was assessed using Pearson's correlation coefficient. Data analysis was performed using Stata version 13. Source data are available online for this figure.
Ileabett M Echevarría‐Vargas et al. EMBO Mol Med. 2018;emmm
© as stated in the article, figure or figure legend